Inhibitors of protein farnesyltransferase as novel anticancer agents.

Junko Ohkanda, David B. Knowles, Michelle A. Blaskovich, Said M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

This paper describes recent progress in the design, synthesis and biological evaluation of inhibitors for the enzyme protein farnesyltransferase (PFTase). This enzyme plays a critical role in the post-translational modification of a range of different intracellular proteins. In particular, PFTase attaches a farnesyl group to the GTPase Ras whose oncogenically mutated form is found in over 30% of human cancers. As a result PFTase inhibitors have been developed as potential cancer therapeutic drugs either by rational design based on the structure of the CAAX carboxyl terminus of Ras or random screening of chemical libraries or natural products. Some of these inhibitors show remarkable inhibition potency against PFTase at subnanomolar concentrations and >1000-fold selectivity compared to the related enzyme geranylgeranyltransferase-I. Certain of these compounds are highly effective at blocking the growth of human tumors in animal models and are now undergoing clinical trials. However, several issues in the research remain unsolved, including the mechanism by which PFTase inhibitors suppress tumor growth. Although it has been established that PFTase inhibitors block prenylation of Ras in vitro, the results in wholecells and animal studies suggest the possibility that proteins other than Ras are affected.

Original languageEnglish (US)
Pages (from-to)303-323
Number of pages21
JournalCurrent Topics in Medicinal Chemistry
Volume2
Issue number3
StatePublished - Mar 2002

Fingerprint

Antineoplastic Agents
ras Proteins
Tumors
Neoplasms
Animals
Small Molecule Libraries
Prenylation
Enzyme Inhibitors
Enzymes
Post Translational Protein Processing
Growth
Biological Products
p21(ras) farnesyl-protein transferase
Screening
Proteins
Animal Models
Clinical Trials
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Chemistry(all)

Cite this

Ohkanda, J., Knowles, D. B., Blaskovich, M. A., Sebti, S. M., & Hamilton, A. (2002). Inhibitors of protein farnesyltransferase as novel anticancer agents. Current Topics in Medicinal Chemistry, 2(3), 303-323.

Inhibitors of protein farnesyltransferase as novel anticancer agents. / Ohkanda, Junko; Knowles, David B.; Blaskovich, Michelle A.; Sebti, Said M.; Hamilton, Andrew.

In: Current Topics in Medicinal Chemistry, Vol. 2, No. 3, 03.2002, p. 303-323.

Research output: Contribution to journalArticle

Ohkanda, J, Knowles, DB, Blaskovich, MA, Sebti, SM & Hamilton, A 2002, 'Inhibitors of protein farnesyltransferase as novel anticancer agents.', Current Topics in Medicinal Chemistry, vol. 2, no. 3, pp. 303-323.
Ohkanda, Junko ; Knowles, David B. ; Blaskovich, Michelle A. ; Sebti, Said M. ; Hamilton, Andrew. / Inhibitors of protein farnesyltransferase as novel anticancer agents. In: Current Topics in Medicinal Chemistry. 2002 ; Vol. 2, No. 3. pp. 303-323.
@article{009a5784a2ec48aa86ab5b357a520f41,
title = "Inhibitors of protein farnesyltransferase as novel anticancer agents.",
abstract = "This paper describes recent progress in the design, synthesis and biological evaluation of inhibitors for the enzyme protein farnesyltransferase (PFTase). This enzyme plays a critical role in the post-translational modification of a range of different intracellular proteins. In particular, PFTase attaches a farnesyl group to the GTPase Ras whose oncogenically mutated form is found in over 30{\%} of human cancers. As a result PFTase inhibitors have been developed as potential cancer therapeutic drugs either by rational design based on the structure of the CAAX carboxyl terminus of Ras or random screening of chemical libraries or natural products. Some of these inhibitors show remarkable inhibition potency against PFTase at subnanomolar concentrations and >1000-fold selectivity compared to the related enzyme geranylgeranyltransferase-I. Certain of these compounds are highly effective at blocking the growth of human tumors in animal models and are now undergoing clinical trials. However, several issues in the research remain unsolved, including the mechanism by which PFTase inhibitors suppress tumor growth. Although it has been established that PFTase inhibitors block prenylation of Ras in vitro, the results in wholecells and animal studies suggest the possibility that proteins other than Ras are affected.",
author = "Junko Ohkanda and Knowles, {David B.} and Blaskovich, {Michelle A.} and Sebti, {Said M.} and Andrew Hamilton",
year = "2002",
month = "3",
language = "English (US)",
volume = "2",
pages = "303--323",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Inhibitors of protein farnesyltransferase as novel anticancer agents.

AU - Ohkanda, Junko

AU - Knowles, David B.

AU - Blaskovich, Michelle A.

AU - Sebti, Said M.

AU - Hamilton, Andrew

PY - 2002/3

Y1 - 2002/3

N2 - This paper describes recent progress in the design, synthesis and biological evaluation of inhibitors for the enzyme protein farnesyltransferase (PFTase). This enzyme plays a critical role in the post-translational modification of a range of different intracellular proteins. In particular, PFTase attaches a farnesyl group to the GTPase Ras whose oncogenically mutated form is found in over 30% of human cancers. As a result PFTase inhibitors have been developed as potential cancer therapeutic drugs either by rational design based on the structure of the CAAX carboxyl terminus of Ras or random screening of chemical libraries or natural products. Some of these inhibitors show remarkable inhibition potency against PFTase at subnanomolar concentrations and >1000-fold selectivity compared to the related enzyme geranylgeranyltransferase-I. Certain of these compounds are highly effective at blocking the growth of human tumors in animal models and are now undergoing clinical trials. However, several issues in the research remain unsolved, including the mechanism by which PFTase inhibitors suppress tumor growth. Although it has been established that PFTase inhibitors block prenylation of Ras in vitro, the results in wholecells and animal studies suggest the possibility that proteins other than Ras are affected.

AB - This paper describes recent progress in the design, synthesis and biological evaluation of inhibitors for the enzyme protein farnesyltransferase (PFTase). This enzyme plays a critical role in the post-translational modification of a range of different intracellular proteins. In particular, PFTase attaches a farnesyl group to the GTPase Ras whose oncogenically mutated form is found in over 30% of human cancers. As a result PFTase inhibitors have been developed as potential cancer therapeutic drugs either by rational design based on the structure of the CAAX carboxyl terminus of Ras or random screening of chemical libraries or natural products. Some of these inhibitors show remarkable inhibition potency against PFTase at subnanomolar concentrations and >1000-fold selectivity compared to the related enzyme geranylgeranyltransferase-I. Certain of these compounds are highly effective at blocking the growth of human tumors in animal models and are now undergoing clinical trials. However, several issues in the research remain unsolved, including the mechanism by which PFTase inhibitors suppress tumor growth. Although it has been established that PFTase inhibitors block prenylation of Ras in vitro, the results in wholecells and animal studies suggest the possibility that proteins other than Ras are affected.

UR - http://www.scopus.com/inward/record.url?scp=0036517177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036517177&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 303

EP - 323

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 3

ER -